Comparing a new injection to aflibercept for wet macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a new eye injection (called QL1207H) against aflibercept, a standard treatment for wet macular degeneration. The goal is to see if the new drug is as effective in improving vision and reducing fluid in the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 50 years old.
- You must have wet age-related macular degeneration (AMD) with active abnormal blood vessels under the center of the retina.
- You must have fluid in the retina (seen on an eye scan) affecting the central vision area.
- Your vision in the affected eye must be moderately to severely impaired (measured on a standard eye chart).
- You cannot have other causes for the blood vessels, uncontrolled glaucoma, or severe myopia (very high nearsightedness).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This trial tests a new medicine called RBS-001, given as an eye injection, against an approved treatment (Eylea) for wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the back of the eye; this study aims to see if the new drug works as well as the current standard.
This trial tests a new eye injection called GB10 for people with wet AMD, a condition that causes rapid vision loss. The goal is to see if it is safe and works to improve or stabilize vision.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This study compares two eye injection treatments for wet age-related macular degeneration (AMD), a condition that causes vision loss. The trial aims to see if the new drug GNR-139 works as well as the standard treatment Eylea.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.